Page 315 - Haematologica April 2020

HSC-GT for herPAP
the Eva Luise Köhler Research Award for Rare Diseases (to GH, JSPS KAKENHI 16K21750 (to TS), Astellas Foundation for NL and TM), Deutsche Forschungsgemeinschaft (Cluster of Research on Metabolic Disorders (to TS) and the NIH Excellence REBIRTH), the German Ministry for Education and R01HL136721 (to TS) R01HL085453 (to BCT), Technology (BMBF, grant 01EK1602A to GH, NL and TM), R01HL118342 (to BCT), U54HL127672 (to BCT).
References
1. Suzuki T, Sakagami T, Young LR, et al. Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. Am J Respir Crit Care Med. 2010; 182(10):1292-1304.
2. Suzuki T, Sakagami T, Rubin BK, et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med. 2008;205(12):2703-2710.
3. Martinez-Moczygemba M, Doan ML, Elidemir O, et al. Pulmonary alveolar pro- teinosis caused by deletion of the GM- CSFRα gene in the X chromosome pseudoautosomal region 1. J Exp Med. 2008; 205(12):2711-2716.
4. Suzuki T, Maranda B, Sakagami T, et al. Hereditary pulmonary alveolar proteinosis caused by recessive CSF2RB mutations. Eur Respir J. 2011;37(1):201-204.
5. Tanaka T, Motoi N, Tsuchihashi Y, et al. Adult-onset hereditary pulmonary alveolar proteinosis caused by a single-base deletion in CSF2RB. J Med Genet. 2011;48(3):205-209.
6. Kaufmann KB, Buning H, Galy A, Schambach A, Grez M. Gene therapy on the move. EMBO Mol Med. 2013;5(11):1642- 1661.
7. Morgan RA, Gray D, Lomova A, Kohn DB. Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned. Cell Stem Cell. 2017;21(5):574-590.
8. NishinakamuraR,WilerR,DirksenU,etal. The pulmonary alveolar proteinosis in gran- ulocyte macrophage colony-stimulating fac- tor/interleukins 3/5 beta c receptor-deficient mice is reversed by bone marrow transplan- tation. J Exp Med. 1996;183(6):2657-2662.
9. KleffV,SorgUR,BuryC,etal.Genetherapy of beta(c)-deficient pulmonary alveolar pro- teinosis (beta(c)-PAP): studies in a murine in vivo model. Mol Ther. 2008;16(4):757-764.
10. Tanaka-Kubota M, Shinozaki K, Miyamoto S, et al. Hematopoietic stem cell transplanta- tion for pulmonary alveolar proteinosis associated with primary immunodeficiency disease. Int J Hematol. 2018;107(5):610-614.
11. Fremond ML, Hadchouel A, Schweitzer C, et al. Successful haematopoietic stem cell transplantation in a case of pulmonary alve- olar proteinosis due to GM-CSF receptor deficiency. Thorax. 2018;73(6):590-592.
12. Happle C, Lachmann N, Skuljec J, et al. Pulmonary transplantation of macrophage progenitors as effective and long-lasting therapy for hereditary pulmonary alveolar proteinosis. Sci Transl Med. 2014;6(250):250ra113.
13. Happle C, Lachmann N, Ackermann M, et al. Pulmonary transplantation of human Induced pluripotent stem cell-derived macrophages ameliorates pulmonary alveo- lar proteinosis. Am J Respir Crit Care Med. 2018;198(3):350-360.
14. Mucci A, Lopez-Rodriguez E, Hetzel M, et al. iPSC-Derived Macrophages Effectively Treat Pulmonary Alveolar Proteinosis in Csf2rb-Deficient Mice. Stem Cell Reports. 2018;11(3):696-710.
15. Takata K, Kozaki T, Lee CZW, et al. Induced-Pluripotent-Stem-Cell-Derived Primitive Macrophages Provide a Platform for Modeling Tissue-Resident Macrophage Differentiation and Function. Immunity. 2017;47(1):183-198.e6.
16. Suzuki T, Arumugam P, Sakagami T, et al. Pulmonary macrophage transplantation therapy. Nature. 2014;514(7523):450-454.
Immunological and metabolic correction after lentiviral vector mediated haematopoi- etic stem cell gene therapy for ADA defi- ciency. Molecular Therapy. 2014;22:S106.
28. Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene ther- apy in patients with Wiskott-Aldrich syn- drome. Science. 2013;341(6148):1233151.
29. Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy bene- fits metachromatic leukodystrophy. Science. 2013;341(6148):1233158.
30. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta- thalassaemia. Nature. 2010;467(7313):318-
17. Nishinakamura R, Nakayama N, Hirabayashi Y, et al. Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit 322. lung pathology and impaired immune
response, while beta IL3 receptor-deficient mice are normal. Immunity. 1995;2(3):211- 222.
18. Mucci A, Kunkiel J, Suzuki T, et al. Murine iPSC-Derived Macrophages as a Tool for Disease Modeling of Hereditary Pulmonary Alveolar Proteinosis due to Csf2rb Deficiency. Stem Cell Reports. 2016; 7(2):292-305.
19. Sallese A, Suzuki T, McCarthy C, et al. Targeting cholesterol homeostasis in lung diseases. Sci Rep. 2017;7(1):10211.
31. Kanter J, Walters MC, Hsieh M, et al. Interim results from a Phase 1/2 clinical study of lentiglobin gene therapy for severe sickle cell disease. Blood. 2017;130(Suppl 1):527-527.
32. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132- 3142.
33. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell pro- liferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415-
20. Hara T, Miyajima A. Two distinct functional
high affinity receptors for mouse inter- 419.
leukin-3 (IL-3). EMBO J. 1992;11(5):1875-
1884.
21. Iyonaga K, Suga M, Yamamoto T, Ichiyasu
34. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 acti- vation after gene therapy for chronic granu- lomatous disease. Nat Med. 2010;16(2):198-
H, Miyakawa H, Ando M. Elevated bron-
choalveolar concentrations of MCP-1 in
patients with pulmonary alveolar pro- 204. teinosis. Eur Respir J. 1999;14(2):383-389.
22. McCarthy C, Lee E, Bridges JP, et al. Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis. Nat Commun. 2018; 9(1):3127.
23. Suzuki T, Trapnell BC. Pulmonary Alveolar Proteinosis Syndrome. Clin Chest Med. 2016;37(3):431-440.
24. Schneider C, Nobs SP, Heer AK, et al. Frontline Science: Coincidental null muta- tion of Csf2ralpha in a colony of PI3Kgamma-/- mice causes alveolar macrophage deficiency and fatal respiratory viral infection. J Leukoc Biol. 2017; 101(2):367-376.
25. Shima K, Suzuki T, Arumugam P, et al. Pulmonary Macrophage Transplantation Therapy in Csf2ra Gene-Ablated Mice: A Novel Model of Hereditary Pulmonary Alveolar Proteinosis in Children. In: B108. CYSTIC FIBROSIS, PRIMARY CILIARY DYSKINESIA, AND ILD. American Thoracic Society; 2017. p. A4857.
26. De Ravin SS, Wu X, Moir S, et al. Lentiviral hematopoietic stem cell gene therapy for X- linked severe combined immunodeficiency. Sci Transl Med. 2016;8(335):335ra57.
27. Gaspar HB, Buckland K, Rivat C, et al. 276.
35. Hetzel M, Suzuki T, Hashtchin AR, et al. Function and safety of lentivirus-mediated gene transfer for CSF2RA-deficiency. Hum Gene Ther Methods. 2017;28(6):318-329.
36. Matute-Bello G, Lee JS, Frevert CW, et al. Optimal timing to repopulation of resident alveolar macrophages with donor cells fol- lowing total body irradiation and bone mar- row transplantation in mice. J Immunol Methods. 2004;292(1-2):25-34.
37. Murphy J, Summer R, Wilson AA, Kotton DN, Fine A. The prolonged life-span of alve- olar macrophages. Am J Respir Cell Mol Biol. 2008;38(4):380-385.
38. Nakata K, Gotoh H, Watanabe J, et al. Augmented proliferation of human alveolar macrophages after allogeneic bone marrow transplantation. Blood. 1999;93(2):667-673.
39. Guilliams M, De Kleer I, Henri S, et al. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J Exp Med. 2013;210(10):1977-1992.
40. Hashimoto D, Chow A, Noizat C, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity. 2013;38(4):792-804.
haematologica | 2020; 105(4)
1157